Prescription for Success?
MarketFoolery
The Motley Fool
4.7 • 1.7K Ratings
🗓️ 16 April 2019
⏱️ 24 minutes
🧾️ Download transcript
Summary
Shares of Johnson & Johnson rise on strong earnings and strong growth in prescription drug sales. AT&T unloads its stake in Hulu. And Walmart announces a fashionable partnership with Kidbox. Analysts Emily Flippen and Jason Moser discuss those stories and share some fashion hits and misses. Thanks to LinkedIn for supporting The Motley Fool. Go to Linkedin.com/fool and get $50 off your first job post.
Transcript
Click on a timestamp to play from that location
| 0:00.0 | Thanks to LinkedIn for supporting market foolery. |
| 0:03.0 | LinkedIn jobs makes it easy to get matched with quality candidates who make the most sense for your role. |
| 0:08.0 | Post a job today at LinkedIn.com slash fool and get $50 off your first job post. |
| 0:16.0 | It's Tuesday, April 16th. |
| 0:18.0 | Welcome to Market Flory. |
| 0:19.0 | I'm Matt Greer and joining me in studio, |
| 0:21.0 | we have Motley Full analyst Jason Moser and Emily |
| 0:24.4 | flipping welcome howdy how we feeling we're great okay well |
| 0:29.4 | Walmart fashion is something we're gonna talk about about. We're also going to talk about the future of Hulu, |
| 0:35.6 | which Jason, I know you're a big fan of Hulu. |
| 0:37.5 | Yeah. |
| 0:38.5 | Things just got a little more interesting there, |
| 0:39.7 | but we begin with Johnson and Johnson shares up around 2% today on stronger than expected |
| 0:46.7 | quarterly earnings. More than half of J&J's revenue coming from prescription |
| 0:51.6 | drug sales. Emily, prescription drug sales. |
| 0:53.0 | Emily, prescription drug sales up by more than 4%. |
| 0:58.0 | Yeah, it's an exciting day for J&J. |
| 1:00.0 | And I think a lot of investors and consumers really only know Johnson and Johnson for maybe |
| 1:05.9 | like Motrin, Tylenol, Neutrogina, but this is an increasingly small part of what Johnson and |
| 1:12.0 | Johnson is doing. And I think they're realizing |
| 1:14.4 | that a lot of their growth is going to start coming from their prescription |
| 1:17.3 | drug sales so it's interesting because for the most part Johnson and Johnson |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.